Literature DB >> 29496565

Endothelial nitric oxide synthase polymorphisms affect the changes in blood pressure and nitric oxide bioavailability induced by propofol.

Gustavo H Oliveira-Paula1, Riccardo Lacchini2, Lucas C Pinheiro1, Graziele C Ferreira1, Marcelo R Luizon1, Waynice N P Garcia3, Luis V Garcia3, Jose E Tanus-Santos4.   

Abstract

Propofol anesthesia is usually accompanied by hypotension, which is at least in part related to enhanced endothelial nitric oxide synthase (NOS3)-derived NO bioavailability. We examined here whether NOS3 polymorphisms (rs2070744, 4b/4a VNTR, rs3918226 and rs1799983) and haplotypes affect the changes in blood pressure and NO bioavailability induced by propofol. Venous blood samples were collected from 168 patients at baseline and after 10 min of anesthesia with propofol 2 mg/kg administered intravenously by bolus injection. Genotypes were determined by polymerase chain reaction and haplotype frequencies were estimated. Nitrite concentrations were measured by using an ozone-based chemiluminescence assay, while NOx (nitrites + nitrates) levels were determined by using the Griess reaction. We found that CT + TT genotypes for the rs3918226 polymorphism, the ba + aa genotypes for the 4b/4a VNTR and the CTbT haplotype were associated with lower decreases in blood pressure and lower increases in nitrite levels after propofol anesthesia. On the other hand, the TCbT and CCbT haplotypes were associated with more intense decreases in blood pressure and higher increases in nitrite levels in response to propofol. Our results suggest that NOS3 polymorphisms and haplotypes influence the hypotensive responses to propofol, possibly by affecting NO bioavailability.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anesthesia; Endothelial nitric oxide synthase; Haplotypes; NOS3 polymorphisms; Nitric oxide; Propofol

Mesh:

Substances:

Year:  2018        PMID: 29496565     DOI: 10.1016/j.niox.2018.02.007

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  5 in total

1.  Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

Authors:  Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

2.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

3.  Propofol Promotes Activity and Tumor-Killing Ability of Natural Killer Cells in Peripheral Blood of Patients with Colon Cancer.

Authors:  Dongshui Liu; Xiaoshan Sun; Yue Du; Minmin Kong
Journal:  Med Sci Monit       Date:  2018-09-03

4.  Propofol Inhibits the Proliferation, Migration, and Stem-like Properties of Bladder Cancer Mainly by Suppressing the Hedgehog Pathway.

Authors:  Gang Li; Xu Zhang; Xiangyang Guo; Yi Li; Chong Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

5.  Molecular mechanism of Chuanxiong Rhizoma in treating coronary artery diseases.

Authors:  Bang-Qiao Yin; Yu-Hong Guo; Yuan Liu; Yang-Yang Zhao; Shan-Mei Huang; Xia-Wei Wei; Heng-Sheng Wang; Ruo-Ya Liu; Ying Liu; Yao-Ping Tang
Journal:  Chin Herb Med       Date:  2021-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.